clinical trial · NCT00647647
Fasting Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® Tablets 250 mg
HealthyTerbinafine Hydrochloride Tablets 250 mgLamisil® Tablets 250 mg
brief summary
The objective of this study was to investigate the bioequivalence of Mylan's terbinafine hydrochloride 250 mg tablets to Novartis' Lamisil® 250 mg tablets following a single, oral 250 mg (1 x 250 mg) dose administered under fasting conditions.
started
Feb 1, 2004
primary completion
Mar 1, 2004
completion
Mar 1, 2004
last updated
Apr 23, 2024
official title
Single-Dose Fasting In Vivo Bioequivalence Study of Terbinafine Hydrochloride Tablets (250 mg; Mylan) to Lamisil® Tablets (250 mg; Novartis) in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol